Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

IRVINE, Calif., March 26 /PRNewswire-FirstCall/ -- NuRx Pharmaceutical Inc.'s (OTC Bulletin Board: NURX) next-generation rexinoid agonist, NRX4204, significantly reduced the number and size of lung tumors and lowered the total tumor volume in mouse models compared to the control group, according to a paper published in Clinical Cancer Research (2007; Vol. 13, Issue 20: 6237-6243).

In addition, the paper showed that NRX4204 caused marked tumor regression in all of the mammary tumors when used therapeutically. Rexinoids regulate cell proliferation, differentiation, and apoptosis pathways.

Entitled "A New Rexinoid, NRX4204, Prevents Carcinogenesis in Both Lung and Mammary Gland," the paper is based on a study that first evaluated the anti-inflammatory effects of NRX4204 and its growth-inhibitory properties in vitro and then measured the compound's ability to prevent and/or treat experimental lung and estrogen receptor (ER)-negative breast cancer in vivo.

"This study demonstrates that NRX4204 is exceptionally potent and not only reduces the number and size of adenocarcinomas in the lung, but it also prevents the development of mammary tumors and induces striking tumor regression in established mammary tumors," said Michael Sporn, Ph.D., professor of pharmacology and toxicology and of medicine at Dartmouth Medical School and the study's principal investigator. "For the first time, NRX4204 also showed effects as an anti-inflammatory agent in cell culture models that are highly relevant for human inflammatory diseases."

Harin Padma-Nathan, M.D., President and CEO of NuRx Pharmaceuticals said: "In this study, NRX4204 exhibited dramatic effects in the prevention of the development of lung cancer and in the prevention and treatment of breast cancer in spontaneous models. We have initiated a Phase I clinical trial and intend to pursue the development of this compound as a treatment for both lung and breast cancer. There are no rexinoid treatm
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... LISBON, Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval ... The inspection, carried out by the FDA Consumer Safety ... initially planned, started on 21 st July and concluded ... to be compliant with the principles and guidelines of Good ...
(Date:7/31/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Gilead (Nasdaq: GILD - Free ... ), AbbVie (NYSE: ABBV - Free Report ) and ... Today, Zacks is promoting its ,Buy, stock recommendations. Get ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Pharmaceutical Corporation (OTC Bulletin Board: PRTT ) announced ... and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company ... The patent portfolio includes innovative pain drugs that address the ... Protect,s Chief Operating Officer, said, "We are very happy to ...
... NEW YORK, Feb. 9, 2011 Reportlinker.com ... is available in its catalogue: ... and Vulnerable Plaque Treatment 2011 ... report details the responses of a comprehensive ...
Cached Medicine Technology:Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 2
(Date:7/31/2014)... study published today in Genes & Development ... Sciences Centre,s DNA Replication group, in collaboration with ... intricate mechanisms involved in the enzyme that governs ... sophisticated system using synthetic, chemical and structural biology ... involved in duplicating genetic information embraces DNA through ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces the ... simplified and predictable with fixed fees across the board, ... international provider of legal discovery management services for law ... apparent that both the courts and legal counsel alike ... complex pricing structure that plagues the litigation support industry. ...
(Date:7/31/2014)... 2014 The Alaska Center for ... new dentist Dr. Jonathan Oudin, DDS, who will begin ... in Barrow, Alaska, for three years. According to Teresa ... Dr. Oudin to help take on new patients. , ... continue growing and serving the greater Anchorage metro community," ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Transplant surgeons often feel ... for burnout, a new study suggests. Nearly ... reported having a low sense of personal accomplishment ... emotionally exhausted, researchers found. "Burnout is common ... study co-author Dr. Marwan Abouljoud, director of the ...
(Date:7/31/2014)... algorithm aimed to diagnose pediatric patients with suspected ... scans, without affecting diagnostic accuracy, Mayo Clinic Children,s ... published in the journal Surgery . , ... acute abdominal pain in children. Appendicitis occurs when ... CT scans are often used to diagnose acute ...
Breaking Medicine News(10 mins):Health News:Molecular gate that could keep cancer cells locked up 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2
... to more false positives, additional work-ups , , THURSDAY, Jan. ... estimating glomerular filtration (eGFR) rates from routine blood work ... with chronic kidney disease, U.S. researchers report. , The ... kidneys over time, and its formula factors in measures ...
... BETHESDA, Md., Jan. 29 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: ... of western healthcare,products and services in the People,s Republic ... third quarter 2009 financial results on Monday,February 9, 2009, ... 8:00 am ET that day to discuss financial results. ...
... Meditation technique may help keep discomfort at bay, study ... Zen meditation appears to reduce sensitivity to moderate pain ... "Previous studies had already shown that teaching patients with ... no one had examined how these effects might come ...
... management system designed to meet unique supply management ... Fla., Jan. 29 Omnicell, Inc. (Nasdaq: ... solutions to acute healthcare facilities, and Shands HealthCare ... chain management systems (formerly known as OptiFlex SS) ...
... and FORT LAUDERDALE, Fla., Jan. 29 Houlihan Smith,& ... into Tri-Tech Health, LLC, (Tri-Tech Health) as announced by,Charles ... The,advisory services were led by Houlihan Smith Managing ... , "We have been working ...
... Cholera Outbreak STAMFORD, Conn., Jan. 29 AmeriCares is ... in an effort to stem a deadly cholera outbreak ... outbreak is one of Africa,s deadliest in 15 years ... is at risk. With limited medical resources and dismal ...
Cached Medicine News:Health News:Kidney Function Test May Not Be Cost-Effective 2Health News:Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Results 2Health News:The Zen Way to Pain Relief 2Health News:The Zen Way to Pain Relief 3Health News:The Zen Way to Pain Relief 4Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 2Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 3Health News:Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC 2Health News:AmeriCares Doubles Aid to Zimbabwe 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: